Lon­za boosts ADC sup­ply ca­pac­i­ty through part­ner­ship ex­pan­sion with un­named ma­jor phar­ma

Af­ter a sum­mer of com­mer­cial and team trou­bles, there’s some good news for Lon­za as it ex­tends its part­ner­ship with an un­named “ma­jor bio­phar­ma­ceu­ti­cal part­ner” to en­hance its an­ti­body-drug con­ju­gate man­u­fac­tur­ing ca­pa­bil­i­ties.

The ex­ten­sion builds on an ex­ist­ing col­lab­o­ra­tion be­tween Lon­za and the se­cret phar­ma com­pa­ny for end-to-end ADC man­u­fac­tur­ing at Lon­za’s Ibex Ded­i­cate Biopark site in Visp, Switzer­land. The deal cov­ers pay­load and mon­o­clon­al an­ti­body man­u­fac­tur­ing as well as bio­con­ju­ga­tion — the process where­by these two parts are co­va­lent­ly linked.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER